Structural requirements for cellular uptake and antisense activity of peptide nucleic acids conjugated with various peptides.
Peptide nucleic acids (PNAs) have shown great promise as potential antisense drugs; however, poor cellular delivery limits their applications. Improved delivery into mammalian cells and enhanced biological activity of PNAs have been achieved by coupling to cell-penetrating peptides (CPPs). Structural requirements for the shuttling ability of these peptides as well as structural properties of the conjugates such as the linker type and peptide position remained controversial, so far. In the present study an 18mer PNA targeted to the cryptic splice site of a mutated beta-globin intron 2, which had been inserted into a luciferase reporter gene coding sequence, was coupled to various peptides. As the peptide lead we used the cell-penetrating alpha-helical amphipathic peptide KLAL KLAL KAL KAAL KLA-NH2 [model amphipathic peptide (MAP)] which was varied with respect to charge and structure-forming properties. Furthermore, the linkage and the localization of the attached peptide (C- vs N-terminal) were modified. Positive charge as well as helicity and amphipathicity of the KLA peptide was all required for efficient dose-dependent correction of aberrant splicing. The highest antisense effect was reached within 4 h without any transfection agent. Stably linked conjugates were also efficient in correction of aberrant splicing, suggesting that a cleavable disulfide bond between CPP and PNA is clearly not essential. Moreover, the placement of the attached peptide turned out to be crucial for attaining antisense activity. Coadministration of endosome disrupting agents such as chloroquine or Ca2+ significantly increased the splicing correction efficiency of some conjugates, indicating the predominant portion to be sequestered in vesicular compartments.
Wolf
Yvonne
Y
Leibniz-Institute of Molecular Pharmacology, Robert-Rössle-Strasse 10, D-13125 Berlin, Germany. wolf@fmp-berlin.de
Pritz
Stephan
S
Abes
Saïd
S
Bienert
Michael
M
Lebleu
Bernard
B
Oehlke
Johannes
J
D016375:Antisense Elements (Genetics) / Q000138:chemical synthesis / Q000235:genetics / Q000494:pharmacology*; D002463:Cell Membrane Permeability; D005786:Gene Expression Regulation / Q000187:drug effects* / Q000235:genetics; D005914:Globins / Q000096:biosynthesis / Q000235:genetics; D006367:HeLa Cells; D006801:Humans; D020135:Peptide Nucleic Acids / Q000138:chemical synthesis / Q000235:genetics / Q000494:pharmacology*; D010455:Peptides / Q000138:chemical synthesis / Q000235:genetics / Q000494:pharmacology*; D017433:Protein Structure, Secondary / Q000235:genetics; D012326:RNA Splicing / Q000187:drug effects* / Q000235:genetics; D014162:Transfection
D016375:Antisense Elements (Genetics); D020135:Peptide Nucleic Acids; D010455:Peptides; D005914:Globins